VOICED : Pfizer dice que su píldora anticovid es 89% efectiva

Pfizer announced that its anticovid pill, Paxlovid, showed high effectiveness in reducing hospitalization and death risks by 89% in a clinical trial involving 1,219 adults across various continents. The positive results prompted Pfizer to seek emergency use authorization from the FDA. Paxlovid is the second anticovid pill after Merck's molnupiravir, which is already approved in the UK. Unlike molnupiravir, Paxlovid is specifically designed to combat COVID-19 by inhibiting the virus's replication machinery.

What percentage did Pfizer's Paxlovid reduce the risk of hospitalization and death in high-risk COVID-19 patients?

• 70%

• 89%

• 95%

• 50%

How many adults participated in Pfizer's clinical trial for Paxlovid?

• 2,000

• 1,219

• 750

• 500

What action did Pfizer decide to take after the positive results of their clinical trial?

• Sell the pill in Europe

• Discontinue the pill

• Seek emergency use authorization

• Continue testing

Which company developed the first anticovid pill approved in the UK?

• Johnson & Johnson

• Pfizer

• Moderna

• Merck

What is the primary function of Pfizer's anticovid pill?

• Increase antibody production

• Reduce fever

• Inhibit virus replication

• Boost immune response